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Abstract: The applications of the 16S rRNA gene pyrosequencing has expanded our knowledge of
the respiratory tract microbiome originally obtained using conventional, culture-based methods.
In this study, we employed DNA-based molecular techniques for examining the sputum microbiome
in bronchiectasis patients, in relation to disease severity. Of the sixty-three study subjects,
forty-two had mild and twenty-one had moderate or severe bronchiectasis, which was classified by
calculating the FACED score, based on the FEV1 (forced expiratory volume in 1 s, %) (F, 0–2 points),
age (A, 0–2 points), chronic colonization by Pseudomonas aeruginosa (C, 0–1 point), radiographic
extension (E, 0–1 point), and dyspnoea (D, 0–1 point). Bronchiectasis was defined as mild,
at 0–2 points, moderate at 3–4 points, and severe at 5–7 points. The mean age was 68.0 ± 9.3 years;
thirty-three patients were women. Haemophilus (p = 0.005) and Rothia (p = 0.043) were significantly
more abundant in the mild bronchiectasis group, whereas Pseudomonas (p = 0.031) was significantly
more abundant in the moderate or severe group. However, in terms of the alpha and beta diversity,
the sputum microbiota of the two groups did not significantly differ, i.e., the same dominant
genera were found in all samples. Further large-scale studies are needed to investigate the sputum
microbiome in bronchiectasis.
Keywords: bronchiectasis; FACED score; microbiome
1. Introduction
Bronchiectasis is a chronic, irreversible airway disease with abnormal dilatation of one or more
bronchi, causing chronic cough and purulent sputum production. Impaired mucociliary clearance
in bronchiectasis patients is associated with continuous or repeated respiratory infection, inducing
a vicious cycle of blockage, inflammation, exacerbation, and damage in the affected bronchi [1].
Bronchiectasis is associated with extended hospitalizations and high mortality, causing a significant
economic burden [2,3].
Prevention of exacerbation, reduction of respiratory symptoms, and stopping the progression
of the disease are important for the management of bronchiectasis [4]. By improving the bronchial
hygiene and decreasing bronchial inflammation, recurrent infection and frequent exacerbation can
be prevented [5]. Therefore, the ability to precisely identify colonizing bacterial species, including
potential pathogens, is important for clinicians who treat bronchiectasis patients.
Conventional, culture-based microbiological analyses identified multiple bacterial pathogens
in bronchiectasis patients, such as Pseudomonas aeruginosa, Haemophilus influenzae, Streptococcus
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pneumoniae, Staphylococcus aureus, and Moraxella catarrhalis. Importantly, previous studies showed that
the P. aeruginosa colonization in bronchiectasis was linked to clinical, functional, and radiographic
deterioration. Although standard culture-based diagnostic methods are widely used, chronic infections
caused by anaerobes or certain bacterial species that barely grow under standard conditions are difficult
to diagnose using these methods [6]. The application of next generation sequencing (NGS), using
16S rRNA gene pyrosequencing has expanded our understanding of the pathogenesis of bronchiectasis
and is helping physicians to select appropriate antibiotic treatments [7].
Martínez-García et al. used five dichotomized variables to develop a scoring system for non-cystic
fibrosis bronchiectasis, known as the “FACED score”, which considers lung function, age, colonization
by P. aeruginosa, radiographic extension, and dyspnoea [8]. The authors conducted a multicenter,
observational study, with eight hundred and nineteen bronchiectasis patients who were classified
according to disease severity, in relation to the five-year all-cause mortality.
In this study, we employed culture-independent, DNA-based molecular techniques for examining
the composition of the bacterial microbiota in sputum samples, in relation to disease severity, which
we derived using the FACED scoring system.
2. Experimental Section
2.1. Study Population
Bronchiectasis was diagnosed by high-resolution computed tomography (HRCT). Patients who
had active tuberculosis or trauma/tuberculosis-related destroyed lungs, were excluded from the study.
Figure 1 shows the patient flow chart. Initially, from 1 April 2017 to 31 August 2017, a total of seventy
patients with bronchiectasis agreed to participate in this prospective study, but seven patients were
excluded from the study because of incomplete data (n = 6), or a low quantity of DNA extracted for
the analysis (n = 1). Therefore, a total of sixty-three patients with bronchiectasis were investigated in
this study.
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Figure 1. Patient flow chart. From 1 April 2017 to 31 August 2017, a total of seventy patients with
bronchiectasis agr ed to participate in this prospective study, but seven patients were excluded from
this study because of incomplete data (n = 6) or an insufficient quantity of DNA extracted for the
analysis (n = 1). PFT, pulmonary function test.
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The severity of bronchiectasis was classified using the FACED score as follows; percentage of
predicted forced expiratory volume in 1 s (FEV1 in %) (F, cut-off 50%, 0–2 points); age (A, cut-off
70 years, 0–2 points); presence of chronic colonization by P. aeruginosa (C, dichotomic, 0–1 point);
radiographic extension (E, number of lobes affected, cut-off two lobes, 0–1 point); and dyspnoea
(D, cut-off grade II on the Medical Research Council scale, 0–1 point). Mild bronchiectasis was
defined as 0–2 points, moderate was 3–4 points, and severe was 5–7 points [8]. Out of the sixty-three
patients, forty-two had mild bronchiectasis, and twenty-one had moderate (n = 15) or severe (n = 6)
bronchiectasis. Demographic data and clinical measurements were collected, including age, sex, body
mass index (BMI), smoking status and amount, respiratory symptoms, pulmonary function test (PFT),
chest CT findings, sputum culture study, and comorbidities.
2.2. Sputum Sample Acquisition Method
Before the sputum acquisition, all patients were asked to rinse their mouth with sterile saline and
to breathe deeply five times. Patients then, immediately, produced the sputum (≥1mL) by repeated
deep breaths and coughing into a sterile container. In patients with no sputum, 5 cc of 3% NaCl was
inhaled using a nebulizer and the induced sputum was collected for the study [9]. Acquired sputum
samples were stored at −70 ◦C, in a freezer, and the DNA extraction was performed within 24 h,
after the sputum acquisition. DNA extraction was performed with a commercial DNA extraction kit
(PowerSoil DNA isolation kit, Mo Bio Laboratories, Inc. Carlsbad, CA, USA). Extracted DNA samples
were stored at −20 ◦C, in a freezer, before the analysis by a polymerase chain reaction (PCR).
2.3. PCR Amplification and Sequencing
Purified DNA was used as a template for the PCR amplification with primers
targeting the V3 and V4 regions of the 16S rRNA gene. The primers were 341F
(5′-TCGTCGGCAGCGTC-AGATGTGTATAAGAGACAG-CCTACGGGNGGCWGCAG-3′) and
805R (5′-GTCTCGTGGGCTCGG-AGATGTGTATAAGAGACAG-GACTACHVGGGTATCTAATCC-3′).
The amplification program was as follows. First, denaturation at 95 ◦C for 3 min was done,
followed by 25 cycles of denaturation at 95 ◦C for 30 s. Primers were annealed at 55 ◦C for
30 s and extended at 72 ◦C for 30 s, using a final elongation at 72 ◦C for 5 min. To attach the
Illumina NexTera barcode, a secondary amplification was carried out with the i5 forward primer
(5′-AATGATACGGCGACCACCGAGATCTACAC-XXXXXXXX-TCGTCGGCAGCGTC-3′; X indicates
the barcode region) and the i7 reverse primer (5′-CAAGCAGAAGACGGCATACGAGAT-XXXXXXXX-
AGTCTCGTGGGCTCGG-3′). The program for the secondary amplification was the same as described
above, except that the amplification cycle was set to eight.
Using 2% agarose gel electrophoresis and a Gel Doc system (BioRad, Hercules, CA, USA), the PCR
amplification products were confirmed and then purified using the QIAquick PCR purification kit
(Qiagen, Valencia, CA, USA). Short fragments (non-target products) were removed using the Ampure
beads kit (Agencourt Bioscience, Waltham, MA, USA). The products were assessed on a Bioanalyzer
2100 (Agilent, Palo Alto, CA, USA) for quality and size, using a DNA 7500 chip.
Mixed amplicons were pooled and an Illumina MiSeq Sequencing system (Illumina, San Diego,
CA, USA) was used for sequencing, which was performed at the Chun Lab, Inc. (Seoul, Korea),
according to the manufacturer’s instructions [10].
2.4. Miseq Pipeline Method
To remove the low-quality reads, quality checks and the filtering of raw reads were performed by
Trimmomatic 0.32 [11]. After the quality control, PANDAseq was used for merging the paired-end
sequence data. With the help of the ChunLab’s program, primers were trimmed (cut off value: 0.8).
Using the HMMER’s hmmsearch program, non-specific amplicons, which do not encode the 16S rRNA,
were detected. The process of denoising the sequences was performed with the DUDE-Seq, and the
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non-redundant reads were extracted through UCLUST-clustering. Taxonomic assignments were
obtained using USEARCH (8.1.1861_i86linux32), as implemented in the EzBioCloud database.
UCHIME7 and the non-chimeric 16S rRNA database from the EzBioCloud were used to find
identify chimeras in the reads, with a best hit similarity rate of less than 97%. Sequence data were
clustered using the CD-HIT8 and the UCLUST5. The alpha diversity indices and rarefaction curves
were estimated using an in-house code.
2.5. Ethics Statement
The Institutional Review Board (IRB) of Seoul National University Bundang Hospital reviewed
and approved this prospective study protocol (IRB approval number: B-1703/386-301). Informed
written consent was obtained from the all patients on the day of sputum collection. All procedures
were performed in accordance with the Declaration of Helsinki.
3. Results
The baseline characteristics of the study population are presented in Table 1. Age was higher
(74.5 ± 5.9 years vs. 64.8 ± 9.0 years) and there were more cases of dyspnoea (33.3% vs. 7.1%),
among patients with moderate/severe bronchiectasis, than among those with mild bronchiectasis
(p < 0.001 and p = 0.012, respectively). Although the percentage of men and smokers was higher in the
moderate/severe group, these differences were not significant (p = 0.285, and p = 0.114, respectively).
Sputum was the most common respiratory symptom in the study population. Table 2 lists the
comorbidities and the results of the pulmonary function tests. There were no significant differences in
comorbidities between the two study groups. Non-tuberculosis mycobacterium (NTM) disease, which
was included as a diagnosis, in 2007 by the American Thoracic Society (ATS)/Infectious Diseases
Society of America (IDSA), was the most common comorbidity in both groups, but there was no
significant difference in the NTM diseases between the two groups (p = 0.721). The prevalence
of NTM was 52.4% in the mild bronchiectasis group, and 57.1% in the moderate/severe group.
The moderate/severe group showed significantly reduced lung function. Forced vital capacity
(FVC, %) was 75.3 ± 19.8 in the moderate/severe group and 88.4 ± 16.5 in the mild group (p = 0.007).
FEV1 (%) was 66.7 ± 24.5 in the moderate/severe group and 88.0 ± 21.1 in the mild group (p = 0.001).
The ratio of FEV1/FVC was also significantly lower in the moderate/severe group (p = 0.001). The value
of the diffusing capacity for carbon monoxide (DLco) was within the normal range in both groups.
Table 1. Baseline characteristics of the study population according to the severity of bronchiectasis.
Mild (n = 42) Moderate or Severe (n = 21) p-Value
Age (years) 64.8 ± 9.0 74.5 ± 5.9 <0.001
Sex, male (%) 18 (42.9) 12 (57.1) 0.285
BMI (kg/m2) 22.0 ± 3.2 22.3 ± 3.5 0.783
Smoking status 0.604
Never smoker 29 (69.0) 13 (61.9)
Ex-smoker 12 (28.6) 8 (38.1)
Current smoker 1 (2.4) -
Smoking amount (pack-year) 4.3 ± 11.1 10.7 ± 19.4 0.114
Respiratory symptom
Dyspnea 3 (7.1) 7 (33.3) 0.012
Cough 14 (33.3) 9 (42.9) 0.580
Sputum 25 (59.5) 8 (38.1) 0.108
Hemoptysis 1 (2.4) 2 (10.0) 0.241
Abbreviations: BMI; body mass index.
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Table 2. Comorbidities and clinical data according to the severity of bronchiectasis.
Mild (n = 42) Moderate or Severe (n = 21) p-Value
Comorbidities
Diabetes mellitus 1 (2.4) 3 (14.3) 0.104
Hypertension 10 (23.8) 6 (28.6) 0.682
Gastroesophageal reflux disease 8 (19.0) 4 (19.0) 1.000
Sinusitis 5 (11.9) 2 (9.5) 1.000
Cardiovascular disease 1 (2.4) 1 (4.8) 1.000
Stroke 3 (7.1) 0 (0.0) 0.545
Liver disease 2 (4.8) 2 (9.5) 0.595
Renal disease 1 (2.4) 1 (4.8) 1.000
Non-tuberculosis mycobacterium 22 (52.4) 12 (57.1) 0.721
Pulmonary function
FVC (%) 88.4 ± 16.5 75.3 ± 19.8 0.007
FEV1 (%) 88.0 ± 21.1 66.7 ± 24.5 0.001
FEV1/FVC ratio 0.71 ± 0.09 0.60 ± 0.16 0.001
DLCO (%) 103.3 ± 22.9 92.8 ± 21.7 0.170
The dominant bacteria among the patients of the two study groups are shown in Table 3 and
Figure 2. Proteobacteria and Firmicutes were the most common phyla. Although the percentage of
Proteobacteria was higher in the moderate/severe bronchiectasis group and that of Actinobacteria was
higher in the mild bronchiectasis group, there were no significant differences in relative abundance,
at the phylum level, between the two study groups (Figure 2A). At the genus level, Haemophilus and
Rothia were significantly more abundant in the mild bronchiectasis group than in the moderate/severe
bronchiectasis group (p = 0.005, and p = 0.043, respectively), whereas Pseudomonas was significantly
more common in the moderate/severe group (p = 0.031) (Figure 2B). Mycobacterium was detected in a
few patients through the 16S rRNA gene sequencing analysis; Mycobacterium_uc_s was detected in
three patients, while Mycobacterium abscessus and the Mycobacterium bisbanense complex were detected
in one patient, each.
Table 3. Abundance of specific bacteria in bronchiectasis, by severity.
Classification
Mild (n = 42) Moderate or Severe (n = 21)
p-ValueTotal
Reads % Occurred
Total
Reads % Occurred
Phylum
Proteobacteria 32,780 50.9 42 31,405 57.0 21 0.814
Firmicutes 16,119 25.1 42 13,090 23.8 21 0.431
Bacteroidetes 8300 12.9 42 6555 11.9 21 0.499
Actinobacteria 3893 6.1 42 1311 2.4 21 0.099
Fusobacteria 2726 4.2 42 2346 4.3 21 0.722
Saccharibacteria_TM7 293 0.5 36 137 0.2 18 0.259
Spirochaetes 146 0.2 35 128 0.2 17 0.862
Tenericutes 48 0.1 24 41 0.1 12 0.842
Synergistetes 10 0.0 24 43 0.1 15 0.227
Genus
Haemophilus 15,663 24.3 42 5767 10.5 21 0.005
Neisseria 8828 13.7 42 10,405 18.9 21 0.618
Streptococcus 7439 11.6 42 6830 12.4 21 0.817
Pseudomonas 3082 4.8 39 9408 17.1 18 0.031
Veillonella 5496 8.5 42 4150 7.5 21 0.444
Prevotella 5243 8.1 42 3830 7.0 21 0.395
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Table 3. Cont.
Classification
Mild (n = 42) Moderate or Severe (n = 21)
p-ValueTotal
Reads % Occurred
Total
Reads % Occurred
Rothia 3181 4.9 42 1089 2.0 21 0.043
Klebsiella 3279 5.1 28 933 1.7 11 0.386
Fusobacterium 1865 2.9 42 1928 3.5 21 0.950
Porphyromonas 1744 2.7 41 1640 3.0 20 0.926
Actinobacillus 544 0.8 34 1265 2.3 19 0.441
Staphylococcus 766 1.2 26 1077 2.0 15 0.810
Leptotrichia 798 1.2 39 404 0.7 19 0.079
AF366267_g 12 0.0 27 1736 3.2 13 0.325
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was not significant (p = 0.277) (Figure 3A). Species richness estimates were not significantly 
different between the two groups, as demonstrated by the abundance-based coverage estimator 
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Figure 2. Abundance of the dominant bacteria in patients with bronchiectasis according to disease
severity: ( ) Phylum level, and (B) genus l vel. Haemophilus and Rothia were significantly mor
abundant in the mild bronchiectasis group than in the moderate/severe bronchiectasis group (p = 0.005,
nd p = 0.043, respectively), and Pseudomonas was significantly more common i t e moderate/severe
group (p = 0.031).
The median number of operational taxonomic unit (OTU) was 189 (Q1: 132, Q3: 252), in the
mild bronchiectasis group, and 157 (112, Q1; 234, Q3) in the moderate/severe group; this difference
was not significant (p = 0.277) (Figure 3A). Species richness estimates were not significantly different
between the two groups, as demonstrated by the abundance-based coverage estimator (ACE, Figure 3B,
p = 0.274) and Chao 1 index (Figure 3C, p = 0.307). The Shannon diversity index was also not
significantly different (Figure 3D, p = 0.550).
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Figure 4. Principal coordinates analysis plot between the ild bronchiectasis group and the
oderate/severe bronchiectasis group.
4. Discussion
In this study, we examined the sputum microbiota of bronchiectasis patients using NGS for the
16S rRNA gene pyrosequencing to determine the relationship between the microbiota composition
and the bronchiectasis severity. Overall, culture-independent, DNA-based molecular techniques
did not identify significant differences between patients with mild bronchiectasis and moderate or
severe bronchiectasis. The OTU values and species richness estimates were not significantly different
between the two groups. Only the abundance of the genera Pseudomonas, Haemophilus, and Rothia were
significantly different between the two groups, according to DNA sequencing. Moreover, a significant
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difference was found in the detection of NTM, using either NGS-based analysis or culture growth-based
methods. However, neither Rothia nor NTM affected the severity of bronchiectasis.
P. aeruginosa is the most common pathogen in patients with NTM disease [12]. In our study,
the relative abundance of the genus Pseudomonas was significantly different between the mild and
the moderate/severe bronchiectasis group. Therefore, we hypothesized that the proportion of NTM
cases would be significantly higher in the moderate/severe bronchiectasis group than in the mild
bronchiectasis group, but this was not confirmed by our data. This observation suggests that while
bronchiectasis severity and progression are affected by the presence of P. aeruginosa, NTM itself
may not have an effect on the bronchiectasis severity. Faverio et al. [13] compared bronchiectasis
patients with pulmonary NTM and those with chronic P. aeruginosa infection, in a prospective study.
Patients with bronchiectasis and pulmonary NTM tended to have cylindrical bronchiectasis and a low
disease severity. Another study investigated the US Bronchiectasis Research Registry and showed
that Pseudomonas was isolated more often from the NTM-uninfected patients with bronchiectasis [14].
These studies demonstrated that NTM is not directly related to the severity of the bronchiectasis.
Interestingly, NTM strains were rarely found using the NGS-based analysis, in our study. This might
have been due to the sensitivity of the method for detecting NTM; the NGS-based analysis might
not yet be optimized for NTM detection, whereas in the acid-fast bacilli (AFB) tests, microbiologists
are trained to identify NTM or tuberculosis, using the optimized growth conditions. This lack of
optimization for NTM detection might be responsible for the difference in detection rates between the
conventional culture method and the NGS-based analysis. Further large-scaled studies are needed to
investigate the optimal method of NTM detection.
Haemophilus was the most common genus in our study, and its relative abundance was significantly
higher in the mild bronchiectasis group, whereas that of Pseudomonas was significantly higher in the
moderate/severe bronchiectasis group. King et al. [15] studied the longitudinal change in microbial
organisms in right-nine patients with bronchiectasis, over 5.7 years. In their study, the relative
abundance of the H. influenza was initially 47%, but this decreased to 40%, during the follow-up
examination, whereas that of P. aeruginosa increased from 12% to 18%. In addition, the authors showed
that the clinical severity of bronchiectasis was higher in patients with P. aeruginosa than in patients
with H. influenza. The authors suggested that the disease progresses from no pathogen to Haemophilus
to Pseudomonas.
Rothia was originally proposed and classified as a member of the Micrococcaceae family, by
Georg & Bronwn in 1967 [16]. Lim et al. [17] found that Rothia mucilaginosa was prevalent in
patients with cystic fibrosis that carried P. aeruginosa. Interestingly, there is no obvious pattern
of synergy or competition between the two organisms. Previous studies have shown that R.
mucilaginosa maybe a lower respiratory pathogen in both immunocompetent and immunocompromised
patients [18–20]. Rothia, mostly R. mucilaginosa, was also a predominant organism in bronchiectasis, in
our study. Although the proportion of Rothia was significantly higher in the mild bronchiectasis group,
the abundance of R. mucilanginosa was not significantly different between the two groups (p = 0.064),
similar to the findings of Lim et al.
Recently, Byun et al. [5] reported the characterization of the lung microbiome in stable
or exacerbated bronchiectasis, using the bronchoalveolar fluid samples from fourteen patients.
The authors found that H. influenza, P. aeruginosa, M. catarrhalis, and Prevotella spp. were common.
Specifically, they suggested that Prevotella and Veillonella could be potent anaerobic pathogens. In our
study, although Prevotella and Veillonella were common in both the mild and the moderate/severe
bronchiectasis groups, the abundances of the two pathogens were not significantly different between
the groups. This may indicate that Prevotella and Veillonella are risk factors for the exacerbation of
bronchiectasis, but are not significantly associated with bronchiectasis severity. The authors also
showed that the species richness, as estimated by the Simpson’s, and Shannon’s indices did not
differ at the genus or the family level, between the clinically stable bronchiectasis group and the
exacerbated bronchiectasis group. Similar to our study results, the number of OTUs, the ACE, Chao
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1, and Shannon’s indices, and PCoA plot did not indicate significant differences between the mild
bronchiectasis group and the moderate/severe bronchiectasis group.
There were some limitations to our study. First, although we used a previously validated method
to acquire the high-quality samples, any sample could have become contaminated while passing
through the oral space. Second, although the DNA sequencing 16S rRNA analysis is sensitive and
more informative than the conventional, culture-based methods, it is limited with regards to the
amplification primer. Only well-known binding sites can be used for the pyrosequencing platforms.
Third, daily diet and antibiotic use of patients was not investigated in this study. If this information
would be available, results of this study would be more informative, with respect to patient history
and the dynamics of the lung microbiome [21].
5. Conclusions
In conclusion, although the abundance of Haemophilus and Rothia differed, significantly,
in relation to the severity of bronchiectasis, the NGS-based technique did not identify significant
differences between the alpha diversity and the beta diversity of the lung microbiomes of the mild
bronchiectasis group and the moderate/severe bronchiectasis group. Respiratory microbial community
in bronchiectasis consisted of several abundant genera that did not significantly differ in relation to
disease severity. Further prospective large-scale studies are needed to investigate the microbiome
in bronchiectasis.
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